Evaxion A/S (EVAX) Q2 2025 Earnings Call Transcript

Evaxion A/S (EVAX) reported its Q2 2025 results, emphasizing significant achievements including being on track for a potential option exercise with MSD in the second half of 2025. Key R&D milestones include EVX-01's 2-year clinical efficacy data accepted for oral presentation at ESMO 2025, completion of treatment in the EVX-01 Phase II trial, and the expansion of its pipeline with EVX-B4. While the business development pipeline remains solid for FY targets, management noted that challenging financial markets and increased regulatory uncertainty are impacting general deal execution.

Analysis

Evaxion A/S reported significant progress in its Q2 2025 update, highlighting that its partnership with MSD remains on track for a potential option exercise in the second half of 2025, which stands as a primary near-term catalyst. The company's lead clinical program, EVX-01, has achieved key milestones, including the completion of treatment in its Phase II trial's main part and the acceptance of 2-year clinical efficacy data for a prestigious oral presentation at the ESMO Congress 2025. This progress, coupled with the expansion of the R&D pipeline to include EVX-B4, signals positive momentum in its development efforts. However, management has introduced a note of caution, stating that while its business development pipeline supports full-year targets, broader execution of deals is being impacted by challenging financial markets and heightened regulatory uncertainty. The appointment of a permanent CFO also suggests a move towards greater management stability.

Key Decisions for Investors

• Investors should closely monitor any announcements related to the MSD partnership, as the potential option exercise in H2 2025 is a major valuation inflection point for the company.
• The upcoming presentation of 2-year EVX-01 data at the ESMO Congress is a critical clinical catalyst; its outcome will heavily influence the perceived value and viability of Evaxion's core asset.
• Consider the management's warning on macroeconomic and regulatory headwinds, as these factors could delay future partnerships or funding activities despite the positive internal pipeline developments.